

Executive Branch Personnel

Public Financial Disclosure Report:

Periodic Transaction Report (OGE Form 278-T)

Filer's Information

Sellinger, Philip

United States Attorney, Department of Justice - Executive Office for United States Attorneys

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Sellinger, Philip [electronically signed on 04/08/2022 by Sellinger, Philip in Integrity.gov] - Filer received a 30 day filing extension.

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Sarah Wasserbly, for James E. Macklin, Certifying Official [electronically signed on 06/01/2022 by Sarah Wasserbly, for James E. Macklin in Integrity.gov]

Other review conducted by

/s/ SADLOWSKI, CAROLINE, Ethics Official [electronically signed on 05/31/2022 by SADLOWSKI, CAROLINE in Integrity.gov]

U.S. Office of Government Ethics Certification

/s/ Granahan, Megan, Certifying Official [electronically signed on 06/27/2022 by Granahan, Megan in Integrity.gov]

Data Revised - Workflow re-designation - 05/31/2022

Transactions

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	Aptose Bioscience	See Endnote	Purchase	02/01/2022	No	\$100,001 - \$250,000
2	Intellia Therapeutics	See Endnote	Purchase	02/01/2022	No	\$50,001 - \$100,000
3	Krystal Biotech, Inc. (KRYB)	See Endnote	Purchase	02/01/2022	No	\$50,001 - \$100,000
4	uniQure	See Endnote	Purchase	02/01/2022	No	\$15,001 - \$50,000
5	enVveno Medical Corp (NVNO)	See Endnote	Purchase	02/01/2022	No	\$15,001 - \$50,000
6	SolarEdge Technologies, Inc. (SEDG)	See Endnote	Purchase	02/01/2022	No	\$15,001 - \$50,000
7	Enphase Energy, Inc. (ENPH)	See Endnote	Purchase	02/01/2022	No	\$15,001 - \$50,000
8	Quest Resource Holding Corp. (QRHC)	See Endnote	Purchase	02/01/2022	No	\$1,001 - \$15,000
9	Cue Biopharma, Inc. (CUE)	See Endnote	Purchase	02/01/2022	No	\$1,001 - \$15,000
10	Taysha Gene Therapies Inc (TSHA)	See Endnote	Purchase	02/01/2022	No	\$1,001 - \$15,000
11	TFF Pharmaceuticals	See Endnote	Purchase	02/01/2022	No	\$1,001 - \$15,000
12	Cue Biopharma, Inc. (CUE)	See Endnote	Sale	03/01/2022	No	\$1,001 - \$15,000
13	Taysha Gene Therapies (TSHA)	See Endnote	Sale	03/01/2022	No	\$1,001 - \$15,000
14	TFF Pharmaceutical	See Endnote	Sale	03/01/2022	No	\$1,001 - \$15,000
15	ImmunoGen, Inc. (IMGN)	See Endnote	Purchase	03/01/2022	No	\$15,001 - \$50,000
16	Atomera Inc (ATOM)	See Endnote	Purchase	03/01/2022	No	\$15,001 - \$50,000
17	Kura Oncology, Inc. (KURA)	See Endnote	Purchase	04/01/2022	No	\$1,001 - \$15,000
18	Syndax Pharmaceuticals, Inc. (SNDX)	See Endnote	Purchase	03/01/2022	No	\$15,001 - \$50,000

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
19	TFF Pharmaceuticals	See Endnote	Purchase	04/01/2022	No	\$15,001 - \$50,000
20	SolarEdge Technologies, Inc. (SEDG)	See Endnote	Sale	04/01/2022	No	\$15,001 - \$50,000
21	Enphase Energy, Inc. (ENPH)	See Endnote	Sale	04/01/2022	No	\$15,001 - \$50,000
22	Atomera Inc (ATOM)	See Endnote	Sale	04/01/2022	No	\$15,001 - \$50,000

Endnotes

PART	#	ENDNOTE
Transactions	1	Filer notified of purchase of top holding on 02/01/22.
Transactions	2	Filer notified of purchase of top holding on 02/01/22.
Transactions	3	Filer notified of purchase of top holding on 02/01/22.
Transactions	4	Filer notified of purchase of top holding on 02/01/22.
Transactions	5	Filer notified of purchase of top holding on 02/01/22.
Transactions	6	Filer notified of purchase of top holding on 02/01/22.
Transactions	7	Filer notified of purchase of top holding on 02/01/22.
Transactions	8	Filer notified of purchase of top holding on 02/01/22.
Transactions	9	Filer notified of purchase of top holding on 02/01/22.
Transactions	10	Filer notified of purchase of top holding on 02/01/22.
Transactions	11	Filer notified of purchase of top holding on 02/01/22.
Transactions	12	Filer notified of sale of top holding on 03/01/22.
Transactions	13	Filer notified of sale of top holding on 03/01/22.
Transactions	14	Filer notified of sale of top holding on 03/01/22.

PART	#	ENDNOTE
Transactions	15	Filer notified of purchase of top holding on 03/01/22.
Transactions	16	Filer notified of purchase of told holding on 03/01/22.
Transactions	17	Filer notified of purchase of top holding on 03/01/22.
Transactions	18	Filer notified of purchase of top holding on 03/01/22.
Transactions	19	Filer notified of purchase of top holding on 04/01/22.
Transactions	20	Filer notified of sale of top holding on 04/01/22.
Transactions	21	Filer notified of sale of top holding on 04/01/22.
Transactions	22	Filer notified of sale of top holding on 04/01/22.

Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. Failure to provide the requested information may result in separation, disciplinary action, or civil action. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (4) to the National Archives and Records Administration or the General Services Administration in records management inspections; (5) to the Office of Management and Budget during legislative coordination on private relief legislation; (6) when the disclosing agency determines that the records are arguably relevant to a proceeding before a court, grand jury, or administrative or adjudicative body, or in a proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant to the proceeding; (7) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another, a public financial disclosure report and any accompanying documents, including statements notifying an employee's supervising ethics office of the commencement of negotiations for future employment or compensation or of an agreement for future employment or compensation; (8) to a Member of Congress or a congressional office in response to an

inquiry made on behalf of and at the request of an individual who is the subject of the record; (9) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to this system of records; (10) on the OGE Website and to any person, department or agency, any written ethics agreement, including certifications of ethics agreement compliance, filed with OGE by an individual nominated by the President to a position requiring Senate confirmation; (11) on the OGE Website and to any person, department or agency, any certificate of divestiture issued by OGE; (12) on the OGE Website and to any person, department or agency, any waiver of the restrictions contained in Executive Order 13770 or any superseding executive order; (13) to appropriate agencies, entities and persons when there has been a suspected or confirmed breach of the system of records, the agency maintaining the records has determined that there is a risk of harm to individuals, the agency, the Federal Government, or national security, and the disclosure is reasonably necessary to assist in connection with the agency's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm; and (14) to another Federal agency or Federal entity, when the agency maintaining the record determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in responding to a suspected or confirmed breach or in preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity, the Federal Government, or national security. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.
